Feature | Left Atrial Appendage (LAA) Occluders | August 01, 2016| Dave Fornell

Update for LAA Occluder Technology News and Trends

Watchman, left atrial appendage closure, LAA occluder

An illustration of a Watchman transcatheter LAA occluder being implanted.

Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in the left atrial appendage (LAA). The standard of care is use of warfarin or newer anticoagulation therapy agents, but there has been growing interest in eliminating the need for these drugs and their associated increased bleeding risks by closing off the LAA to prevent clot formation. Device therapy now exists for both open surgical and transcatheter LAA occlusion. 

Below are links to recent DAIC articles that offer an update on this cardiovascular technology area:

 

Occluding the Left Atrial Appendage (LAA)

VIDEO - Post-FDA Approval Experience of LAA Occluders at ACC.16

FDA Approves Pivotal Trial for St, Jude's Amulet LAA Occluder

American College of Cardiology Launches Left Atrial Appendage Occlusion Registry

Societies Issue Recommendations for Left Atrial Appendage Occlusion

Biosense Webster Acquires Coherex Medical LAA Occluder Technology

Medicare Will Cover Watchman Left Atrial Appendage Closure Device

AtriCure Receives FDA Clearance for New AtriClip Device

New Study Demonstrates Cost-Effectiveness of Watchman Device

Boston Scientific Receives CE Mark For Next-generation Watchman FLX LAA Closure Device

FDA Announces Safety Issues With Lariat Left Atrial Appendage (LAA) Closure Device

SentreHeart Receives CE Mark for Lariat Suture Delivery Device

AtriCure Receives CE Mark for AtriClip PRO2 Device

New Data Supports St. Jude Medical FFR and LAA Closure Technology

AtriCure Announces First Patient Enrolled in FROST Cryoanalgesia Study

SentreHEART Receives FDA Approval for AMAZE Trial of Lariat Suture Delivery Device

Valley Hospital Begins Enrollment for aMAZE Trial

AtriCure Enrolls First Patient in ATLAS Study

Role of Interventional Echocardiography in Transcatheter Structural Heart Procedures

 

Related Content

Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for...
Overlay Init